Our Pipeline
Lead Candidates
Trastuzumab-based antibody-drug conjugate
Our lead product is an antibody polar drug conjugate (APDC) developed using our proprietary OmniLink® technology. This APDC, like the approved Kadcyla® consists of the cytotoxic maytansinoid drug conjugated to the trastuzumab antibody. With our proprietary Polarpeutic and linker technologies, the same trastuzumab-maytansinoid combination carries two to three times more drug per antibody compared to Kadycla® with durations of cancer cell killing efficacy exceeding those of Kadcyla® and Enhertu® in multiple preclinical tumor xenograft models. We are planning to move the candidate forward into preclinical and early phase clinical development with metastatic breast cancer as the initial indication with further indication expansion expected as development progresses.
Cancer immunotherapy
Our technology platform extends beyond traditional treatments utilizing cytotoxic drugs. For our second lead candidate, we successfully applied our technologies to create drug product candidates for cancer treatments via immunotherapy. Instead of cytotoxic drugs, a Polarpeutic agonist of a toll-like receptor (TLR) is conjugated to the antibody, which recruits immune cells to the tumor cells and activates them in situ. Initial results from the gastric cancer tumor xenograft model are highly successful and demonstrated full tumor elimination. Furthermore, subsequent challenge of repeat tumor inoculation showed robust inhibition of tumor growth in the treated animals. Results are indicative of long term immune memory against new tumor formation.
Product Pipeline & Platform Technology Applications
Dual-payload antibody drug conjugates
Traditional ADCs consist of a single type of cytotoxic payload conjugated onto the antibody. We have been successful in conjugating a combination of different cytotoxic payloads onto our APDC, including maytansinoids, irinotecan derivatives, camptothecin analogues, and tyrosine kinase inhibitors. The combination of different Polarpeutic payloads creates opportunities for more effective tumor killing through multiple mechanisms synergistically that are more difficult for the cancer to develop resistance against. We are investigating different types of payloads for an optimized combination as a future candidate in the product pipeline.